Core Viewpoint - Avoro Capital Advisors LLC has reduced its stake in Amicus Therapeutics by 16.5%, indicating a shift in institutional investment sentiment towards the biopharmaceutical company [2]. Institutional Holdings - Avoro Capital Advisors LLC now holds 15,025,000 shares of Amicus Therapeutics after selling 2,975,000 shares, representing about 1.5% of its investment portfolio and making it the 20th largest holding [2]. - Other large investors have also adjusted their positions, with Goldman Sachs increasing its stake by 7.7% to 2,703,577 shares valued at $22,061,000 [3]. - UBS AM increased its stake by 11.9% to 1,072,474 shares valued at $8,751,000 [3]. - Intech Investment Management LLC grew its stake by 37.1% to 170,922 shares valued at $1,395,000 [3]. - Strs Ohio and Bank of Montreal Can acquired new positions valued at approximately $30,000 and $144,000, respectively [3]. Insider Transactions - Insider David Michael Clark sold 25,643 shares at an average price of $11.00, totaling $282,073, resulting in an 8.63% decrease in his position [4]. - CEO Bradley L. Campbell sold 77,926 shares at an average price of $10.86, totaling $846,276.36, leading to a 6.45% decrease in his ownership [4]. - Insiders sold a total of 226,711 shares worth $2,887,822 over the last three months, with insiders owning 2.20% of the stock [4]. Analyst Ratings - Jefferies Financial Group reissued a "hold" rating with a price target of $14.50, down from $16.00 [5][6]. - Weiss Ratings issued a "sell (d-)" rating, while Cantor Fitzgerald downgraded the stock from "overweight" to "hold" with a price target reduction from $21.00 to $14.50 [6]. - The consensus rating for Amicus Therapeutics is "Hold" with an average target price of $15.39, with three analysts rating it as a Buy, nine as Hold, and one as Sell [6]. Stock Performance - Amicus Therapeutics shares opened at $14.37, with a market cap of $4.51 billion and a price-to-earnings ratio of -179.63 [7]. - The stock has a 12-month low of $5.51 and a high of $14.39, with a quick ratio of 1.88 and a current ratio of 2.84 [7]. Earnings Results - The company reported an EPS of $0.10 for the last quarter, missing the consensus estimate of $0.13 by $0.03 [8]. - Revenue for the quarter was $185.21 million, slightly above analyst estimates of $185.00 million, representing a year-over-year increase of 23.7% [8]. Company Profile - Amicus Therapeutics focuses on developing treatments for rare and orphan diseases, specializing in pharmacological chaperones and gene therapy for lysosomal storage disorders [9]. - The company's lead product, Galafold (migalastat), is approved for treating Fabry disease in patients with amenable genetic variants [10].

Core Insights - Chiesi Global Rare Diseases and Protalix BioTherapeutics received a negative opinion from the CHMP of the EMA regarding the approval of a new dosing regimen for Elfabrio (pegunigalsidase alfa) [1][2] - The proposed regimen of 2 mg/kg every 4 weeks was not deemed to have sufficient efficacy compared to the currently approved regimen of 1 mg/kg every 2 weeks [1][2] Company Overview - Chiesi Global Rare Diseases is a unit of the Chiesi Group focused on innovative therapies for rare diseases [1][16] - Protalix BioTherapeutics specializes in developing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system [1][19] - Both companies are committed to reducing the treatment burden for patients with Fabry disease [2][20] Clinical Trial Insights - The CHMP review was based on data from the BRIGHT trial and its extension study, which had a median exposure of almost six years [2] - The data from these studies, along with modeling and exposure-response analyses from prior trials, were insufficient to demonstrate similar efficacy for the new dosing regimen [2] Fabry Disease Context - Fabry disease is a rare lysosomal storage disorder caused by mutations in the GLA gene, leading to serious health complications [11][12] - Early detection and access to treatment are critical for managing symptoms and slowing disease progression [12] Safety Information - Elfabrio is indicated for adults with confirmed Fabry disease and has been associated with hypersensitivity reactions, including anaphylaxis [3][4] - In clinical trials, 14% of patients experienced hypersensitivity reactions, with 3% experiencing anaphylaxis [6][9]